Group 1 - The core viewpoint of the article is that Kehua Bio (002022) has partnered with Waters to provide a dual-brand high-performance liquid chromatography-tandem mass spectrometry solution, which includes a series of equipment and testing reagents [1] - The solution aims to cover areas from pre-pregnancy precise cause screening, nutritional monitoring during pregnancy, to newborn disease prevention, thereby supporting better reproductive health [1] - The company advises investors to be cautious of concept speculation and to make rational investment decisions while being aware of investment risks [1]

Core Viewpoint - The company, Kehua Bio-Engineering (002022), is leveraging its immune technology platform to develop tumor marker detection reagents for early screening and auxiliary diagnosis of cancers such as liver, stomach, and lung cancers [1] Group 1: Product Development - The company has developed tumor marker detection reagents that can be used in conjunction with its universal detection instruments for early cancer screening and auxiliary diagnosis [1] - A subsidiary, Tianlong, has developed products based on fluorescence PCR technology that assist in cancer screening, including HPV detection kits for cervical cancer and EB virus detection kits for nasopharyngeal cancer [1]

科华生物（002022.SZ）7月31日在投资者互动平台表示，公司与沃特世公司（Waters）有合作，在临床 质谱领域，双方合作推出了两款产品（ACQUITY UPLC I-Class PLUS/ Xevo TQ-S cronos System和 ACQUITY UPLC I-Class PLUS / Xevo TQ-Loong System）并获得了国家医疗器械注册证。本次合作中双 方采用了"双品牌"模式，将以超高效液相色谱串联质谱为核心技术，构建"前处理自动化+质谱检测+试 剂配套"的一体化平台，覆盖营养代谢、药物浓度监测、内分泌激素检测、生物标志物分析和临床毒理 研究等五大核心领域，赋能精准医疗。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：公司与Waters有合作吗？是关于哪方面的？ ...

Group 1 - The company Kewah Bio announced the convening of its 10th Board of Directors meeting on July 31, 2025, via telecommunication voting [2] - The meeting reviewed the proposal regarding the appointment of the company's Chief Financial Officer [2] - For the year 2024, the company's revenue composition is entirely from the biopharmaceutical sector, accounting for 100.0% [2]

Group 1 - The core business of Kehua Bio is entirely focused on the biopharmaceutical sector, with a revenue composition of 100% from biological products for the year 2024 [1] Group 2 - On July 31, Kehua Bio announced the resignation of Ms. Luo Fang from the position of Chief Financial Officer due to retirement, along with her other roles in the company's subsidiaries [3] - The company has appointed Mr. Zang Xianfeng as the new Chief Financial Officer, following a nomination by the company's president and approval by the board of directors [3]

Core Viewpoint - The company Kewah Bio (002022) has developed a monkeypox nucleic acid detection reagent based on its fluorescence PCR technology platform, which has received EU CE and UK MHRA certifications [1] Group 1: Product Development and Certification - The monkeypox detection reagent can provide results in 40 minutes using a one-tube method [1] - The product specifically detects nucleic acid fragments of the monkeypox virus, enabling rapid identification of the virus [1] - The reagent is currently used in several provincial and municipal disease control centers and customs inspection units in China, and it is also being exported to multiple countries [1] Group 2: Financial Impact - The sales revenue from this product is currently small and has not significantly impacted the company's consolidated revenue [1]

Core Points - The company announced the resignation of its Chief Financial Officer, Ms. Luo Fang, due to retirement [1] - The company appointed Mr. Zang Xianfeng as the new Chief Financial Officer, effective from the date of the board meeting approval until the end of the current board's term [1]

科华生物7月31日公告，公司董事会近日收到财务总监罗芳的书面辞职报告，罗芳因退休申请辞去公司 财务总监职务，同时一并辞去担任的公司下属子公司其他职务，辞职报告自送达公司董事会之日起生 效。公司于2025年7月31日召开第十届董事会第十四次会议，审议通过了《关于聘任公司财务总监的议 案》，聘任臧显峰为公司财务总监，任期自本次董事会审议通过之日起至第十届董事会任期届满之日 止。 ...

| 证券代码：002022 | 证券简称：科华生物 | 公告编号：2025-037 | | --- | --- | --- | | 债券代码：128124 | 债券简称：科华转债 | | 特此公告。 公司董事会对罗芳女士在任职期间为公司发展所做出的贡献表示衷心感谢！ 二、公司聘任财务总监情况 公司于 2025 年 7 月 31 日召开第十届董事会第十四次会议，审议通过了《关 于聘任公司财务总监的议案》，经公司总裁提名，董事会提名委员会、审计委员 会审核，公司董事会同意聘任臧显峰先生为公司财务总监（简历附后），任期自 本次董事会审议通过之日起至第十届董事会任期届满之日止。 上海科华生物工程股份有限公司 关于变更公司财务总监的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、公司财务总监辞职情况 上海科华生物工程股份有限公司（以下简称"公司"）董事会于近日收到公 司财务总监罗芳女士递交的书面辞职报告，罗芳女士因退休申请辞去公司财务总 监职务，同时一并辞去担任的公司下属子公司其他职务。罗芳女士担任财务总监 的原定任期至第十届董事会届满之日（2027 年 3 ...

证券代码：002022 证券简称：科华生物 公告编号：2025-036 债券代码：128124 债券简称：科华转债 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 上海科华生物工程股份有限公司（以下简称"公司"）第十届董事会第十四 次会议（以下简称"本次会议"或"会议"）通知于2025年7月30日以邮件方式送 达全体董事、监事及高级管理人员，会议于2025年7月31日以通讯表决的方式召 开。本次会议应参会董事9人，实际参会董事9人（包含3名独立董事）。本次会议 由公司董事长李明先生主持，会议的召开符合《中华人民共和国公司法》、《上海 科华生物工程股份有限公司章程》和《上海科华生物工程股份有限公司董事会议 事规则》的有关规定。 二、董事会会议审议情况 （一）审议通过《关于聘任公司财务总监的议案》 经公司总裁提名，董事会提名委员会、审计委员会审核，公司董事会同意聘 任臧显峰先生为公司财务总监，任期自本次董事会审议通过之日起至第十届董事 会任期届满之日止。 具体详见公司于同日在《证券时报》、《中国证券报》、《上海证券报》及巨潮 资讯网（htt ...